Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.68, missing the estimate of USD -1.22.

Financial Results

Cash Position

• Cash, cash equivalents, and investments were $25.2 million as of September 30, 2025, compared to $51.3 million as of December 31, 2024.
• Net cash used in operations was $26.3 million for the nine months ended September 30, 2025, compared to $71.2 million for the nine months ended September 30, 2024.

Research and Development (R&D) Expenses

• R&D expenses were $2.8 million for the quarter ended September 30, 2025, compared to $17.9 million for the quarter ended September 30, 2024.

General and Administrative (G&A) Expenses

• G&A expenses were $4.1 million for the quarter ended September 30, 2025, compared to $7.6 million for the quarter ended September 30, 2024.

Net Loss

• Net loss was $6.6 million, or $1.68 per share, for the quarter ended September 30, 2025, compared to a net loss of $28.7 million, or $7.46 per share (on a split-adjusted basis), for the quarter ended September 30, 2024.

Outlook / Guidance

• Athira Pharma continues to explore strategic alternatives focusing on maximizing stockholder value.
• The company remains encouraged by the promising data supporting the continued development of ATH-1105 as a potential therapy for ALS.
• Athira plans to advance the ATH-1105 program into ALS patients to bring a potential novel therapy to those in need of an effective treatment option.